Xolair (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies
- In the phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate response to intranasal corticosteroids[1]
- Omalizumab demonstrated a safety profile consistent with previous research for approved conditions of chronic spontaneous urticaria and severe allergic asthma[1]
- CRSwNP impacts up to 4 percent of people worldwide, and the prevalence increases with age[2]
# # #